Sagility Limited
Financial trend (98/100) does the heavy lifting; momentum (52/100) is the drag.
Buy zoneOur blended model reads Sagility Limited as a Strong Buy at 79/100. At ₹44.87 it trades below our blended DCF and relative-multiples fair value of ₹62.46, about 39% upside to that estimate — we read it as undervalued by 39%. On 19.5x trailing earnings it sits cheaper than the Information Technology median of about 31.6x. The price is about 18% below its 52-week high of ₹54.53 and 23% above the low of ₹36.35. Financial health scores 88/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹56.2 implies about 25% upside across 10 analysts. It clears 10 of 11 investability checks, with durability 72, valuation 83 and momentum 52 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹49.97.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-17.71% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy79Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.11x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 28%
- Pass: Earnings growing: 44%
- Pass: Net margin ≥ 10%: 13.0%
- No data: Current ratio > 1.5
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.5
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Annual financials
Shareholding
- Promoter50.9%
- Institutions20.3%
- Public & other28.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 4.5.
- High Piotroski quality score (7/9).
Opportunities
- Earnings growing (44% YoY).
- Revenue growing (28% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~39% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
About Sagility Limited
Sagility Limited provides business process management services to healthcare and insurance sectors across India, Jamaica, the Philippines, the United States, and Colombia. Its offerings include claims management, cost containment, member and provider engagement, enrollment, benefits plan building, payment integrity, billing, credentialing, clinical and case management, provider network operations, analytics, and front and back-office administration.
Sagility Limited — frequently asked questions
Is Sagility Limited a buy, hold or sell?
StocksWizard currently rates Sagility Limited (SAGILITY) a Strong Buy, based on a blended score of 79/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Sagility Limited's fair value?
Our blended DCF and relative-valuation model estimates Sagility Limited's fair value at about ₹62.46, versus a current price of ₹44.87 — roughly 39% upside. On that basis the stock looks undervalued by 39%.
Is Sagility Limited financially healthy?
Sagility Limited scores 88/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Sagility Limited's share price performed?
Sagility Limited is up 7% over three months, and last traded at ₹44.87. Past performance doesn't predict future returns.
More in Information Technology
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.